Perrigo Company

-$0.77 (-2.1%)
Closing price November 30, 2021
With the potential for a year-end rally looking better after Monday's market action, many investors are turning their attention to end-of-the-year portfolio restructuring.
Thursday's top analyst upgrades, downgrades and initiations include Apollo Global, Avago Technologies, CyberArk Software, First Solar, JC Penney, KKR, Lululemon Athletica, MobileEye, Perrigo and...
Wednesday's top analyst upgrades, downgrades and initiations include Apple, Bluebird, Exxon Mobil, Kinder Morgan, Kinross Gold, Lending Club and Perrigo.
Mylan announced Monday that it would be conducting a share repurchase for up to $1 billion, in a much faster timeline for repurchasing than most companies would give.
The biotech companies 24/7 Wall St. has picked stood out from the rest with incredible gains or losses over the course of the past week.
We scanned the Merrill Lynch stock coverage universe for specialty pharmaceutical stocks rated Buy and found three top companies that have been crushed.
Mylan announced Tuesday, in conjunction with the Irish Takeover Panel, that Perrigo had made misleading statements to shareholders.
Source: ThinkstockWith biotech and specialty pharmaceutical stocks, catalysts and binary events can drive the stocks much higher, or in some cases much lower if the outcome is not what Wall Street...
Teva could be about to enter the largest generic market by prescription in the world, which may tip the scales in its favor when it comes to wooing Mylan shareholders.
Tuesday's top analyst upgrades, downgrades and initiations include Newmont Mining, Vodafone, Yelp, Western Digital, American Airlines and AT&T.
Source: ThinkstockTeva Pharmaceutical Industries Ltd. (NYSE: TEVA) is trying to transform itself by making its generics business even larger if it can pull off its desire to acquire Mylan N.V....
If there ever was a perfect storm for large pharmaceutical and big-cap biotech companies to make acquisitions to enhance growth it is now.
S&P Capital IQ released a report regarding the performance of companies in terms of earnings and revenue.
Teva Pharmaceutical Industries has just approached Mylan with a public takeover bid valued at $82 per share in cash and stock.
Independent research firm Argus has weighed in on Mylan and Perrigo prior to the acquisition.